| AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca |
| Completed | 4 | 530 | Europe, Canada, US, RoW | andexanet alfa, Usual Care | Alexion Pharmaceuticals, Inc. | Acute Intracranial Hemorrhage | 05/23 | 08/23 | | |
| Withdrawn | 3 | 800 | NA | Andexanet alfa, Andexxa®, Ondexxya®, Usual Care | AstraZeneca | Urgent Surgery | 01/27 | 09/27 | | |
4445a: A Phase 2 study evaluating andexanet alfa and XARELTO® (rivaroxaban) |
|
|
| Ongoing | 2 | 0 | RoW | andexanet alfa (PRT4445) | Portola | Healthy volunteers | | | | |
|
|
4445c: Study evaluating andexanet alfa with Lovenox® (enoxaparin) |
|
|
| Ongoing | 2 | 0 | RoW | andexanet alfa (PRT4445) | Portola | Healthy volunteers | | | | |
2020-004898-41: Reperfusion thrombolytic therapy for ischemic stroke in patients on the non-vitamin K antagonist oral anticoagulants. Reperfuzjne leczenie trombolityczne udaru niedokrwiennego mózgu u pacjentów leczonych doustnymi lekami przeciwzakrzepowymi nie należącymi do grupy antagonistów witaminy K |
|
|
| Not yet recruiting | 2 | 300 | Europe | Praxbind, Ondexxya, Actilyse, Solution for infusion, Powder for solution for infusion, Powder and solvent for solution for infusion, Praxbind, Ondexxya, Actilyse | MEDICAL UNIVERSITY OF GDAŃSK, Medical Research Agency | Acute ischemic stroke Udar niedokrwienny, Acute ischemic stroke Udar niedokrwienny, Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-000374-21: A phase 2 clinical trial to study effect of andexanet alfa for patients who require urgent surgery. |
|
|
| Not yet recruiting | 2 | 100 | Europe | andexanet alfa 200 mg vial, ALXN2070, Powder for solution for infusion, Ondexxya® | Alexion Pharmaceuticals, Inc, Alexion Pharmaceuticals, Inc. | Need for FXa inhibitor reversal in patients undergoing urgent surgery., Urgent need for surgery AND recent ingestion of blood thinners., Not possible to specify | | | | |
NCT05898412: Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya |
|
|
| Recruiting | N/A | 100 | Europe | Andexanet alfa | AstraZeneca, LOGEX Healthcare Analytics Amsterdam The Netherlands | Hemorrhage | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 141 | Europe | | University Hospital, Essen | Intracranial Hemorrhages | 07/24 | 12/24 | | |
NCT05454787: Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation) |
|
|
| Recruiting | N/A | 300 | Japan | | AstraZeneca | Life Threatening Bleeding, Factor Xa Inhibitor | 05/25 | 05/25 | | |
